Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Kabi, is a fluoroquinolone antibiotic presented as an injectable solution for intravenous use. It is employed to treat a range of serious bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, skin‑structure infections and complicated intra‑abdominal infections.

GNH USA supplies Moxifloxacin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare institutions, including tertiary care centers and specialty clinics.

Moxifloxacin is a fluoroquinolone antibiotic indicated for several bacterial infections affecting the respiratory, skin and intra‑abdominal systems. - Community‑acquired pneumonia: effective eradication of susceptible pathogens, leading to clinical improvement and resolution of infection. - Acute bacterial sinusitis: rapid reduction of sinus inflammation and bacterial load, relieving symptoms. - Acute bacterial exacerbation of chronic bronchitis: helps restore lung function by eliminating causative bacteria. - Skin and skin‑structure infections: provides bactericidal activity against common Gram‑positive and Gram‑negative organisms. - Complicated intra‑abdominal infections: achieves deep tissue penetration to treat polymicrobial infections following surgery.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Injection site pain or phlebitis

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation and cardiac arrhythmias - Clostridioides difficile–associated diarrhea - Severe hypersensitivity reactions including anaphylaxis

When using Moxifloxacin, clinicians should observe several safety considerations to minimize risk. - Assess renal function: adjust therapy in patients with impaired clearance. - Monitor cardiac rhythm: avoid use in patients with known QT prolongation. - Avoid concomitant QT‑prolonging drugs: limit risk of arrhythmias. - Use with caution in patients with tendon disorders: discontinue if pain or inflammation occurs. - Adjust dose in hepatic impairment: follow prescribing information for liver dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids or supplements containing aluminum, magnesium, calcium, or iron: chelate the drug and markedly reduce absorption. - Co‑administration with other fluoroquinolones: increases risk of additive toxicity. - Concurrent use with drugs that prolong QT interval (e.g., macrolides, antiarrhythmics): may cause serious cardiac events. - Warfarin: may enhance anticoagulant effect and raise INR. - Systemic corticosteroids: increase risk of tendon rupture.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase central nervous system stimulation. - Theophylline: elevated plasma concentrations can lead to toxicity. - Cyclosporine: higher levels may occur, requiring monitoring. - Oral contraceptives: reduced hormonal efficacy, consider alternative contraception. - Diabetic agents (e.g., insulin, sulfonylureas): potential for hypoglycemia, monitor glucose.